Since natriuretic peptides were successfully integrated into the clinical practice of heart
failure (HF), the possibility of using new biomarkers to advance the management of affected …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

BACKGROUND Until recently, biomarker testing in heart failure (HF) syndromes has been
viewed as an elective supplement to diagnostic evaluation of patients suspected to suffer …

Plasma biomarkers are useful tools in the diagnosis and prognosis of heart failure (HF). In
the last decade, numerous studies have aimed to identify novel HF biomarkers that would …

Heart failure (HF) biomarkers have dramatically impacted the way HF patients are evaluated
and managed. B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are the …

Biomarkers play an important role in heart failure. They provide us information about the
mechanisms involved in specific types of heart failure and can identify patients at higher risk …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost,
morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis …

BACKGROUND Heart failure (HF) is a complex syndrome with an enormous societal burden
in terms of cost and morbidity and mortality. Natriuretic peptide (NP) testing is now widely …